Robyn Karnauskas
Stock Analyst at Truist Securities
(1.89)
# 3,056
Out of 4,868 analysts
183
Total ratings
42.04%
Success rate
-1.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABCL AbCellera Biologics | Maintains: Buy | $28 → $10 | $3.47 | +188.18% | 2 | May 16, 2025 | |
| AMGN Amgen | Maintains: Hold | $333 → $298 | $289.63 | +2.89% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $46.84 | +38.77% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $79.29 | +38.73% | 11 | Jan 8, 2025 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $108.00 | -23.15% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $185.49 | +13.21% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $1.91 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $126.54 | +168.69% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $2.30 | +1,030.43% | 2 | May 15, 2024 | |
| CHRS Coherus Oncology | Maintains: Buy | $8 → $7 | $0.77 | +811.93% | 13 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,135 | $513.58 | +121.00% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $1.65 | +506.06% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $2.75 | +227.27% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $74 | $16.83 | +339.69% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $11.44 | +101.05% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $15.86 | +202.65% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $8.51 | +487.54% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $850 | $785.03 | +8.28% | 4 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $448.40 | +13.29% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $23.88 | +50.75% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $50.43 | -50.43% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.73 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $55.24 | +153.44% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $150 | $0.12 | +122,649.59% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $1.21 | +478.51% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $15.10 | +264.24% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.29 | - | 4 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $28.58 | +1,019.66% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $3.53 | +324.93% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.41 | +633.14% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $0.35 | +24,151.07% | 1 | Oct 8, 2020 |
AbCellera Biologics
May 16, 2025
Maintains: Buy
Price Target: $28 → $10
Current: $3.47
Upside: +188.18%
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $289.63
Upside: +2.89%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $46.84
Upside: +38.77%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $79.29
Upside: +38.73%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $108.00
Upside: -23.15%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $185.49
Upside: +13.21%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.91
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $126.54
Upside: +168.69%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $2.30
Upside: +1,030.43%
Coherus Oncology
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $0.77
Upside: +811.93%
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $513.58
Upside: +121.00%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $1.65
Upside: +506.06%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $2.75
Upside: +227.27%
Mar 25, 2024
Reiterates: Buy
Price Target: $74
Current: $16.83
Upside: +339.69%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $11.44
Upside: +101.05%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $15.86
Upside: +202.65%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $8.51
Upside: +487.54%
Mar 22, 2024
Reiterates: Buy
Price Target: $850
Current: $785.03
Upside: +8.28%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $448.40
Upside: +13.29%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $23.88
Upside: +50.75%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $50.43
Upside: -50.43%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $1.73
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $55.24
Upside: +153.44%
Sep 6, 2023
Reiterates: Buy
Price Target: $150
Current: $0.12
Upside: +122,649.59%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $1.21
Upside: +478.51%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $15.10
Upside: +264.24%
Dec 6, 2022
Downgrades: Hold
Price Target: n/a
Current: $2.29
Upside: -
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $28.58
Upside: +1,019.66%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $3.53
Upside: +324.93%
Nov 11, 2020
Initiates: Buy
Price Target: $25
Current: $3.41
Upside: +633.14%
Oct 8, 2020
Initiates: Buy
Price Target: $85
Current: $0.35
Upside: +24,151.07%